New Clinical Trial Data Presented at ASCO 2018: How Will it Change How you Practice?Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr David Spigel discusses the 2 major themes highlighted at ASCO 2018: the use of cancer biomarkers to achieve precision therapy, and fine tuning treatment of patients with immunotherapy with respect to who to treat, how to treat, and how to predict clinical outcomes.
Emily Knight presents why quality of life is a big issue in polycythemia vera and how she helps patients in management Supported through funding from Incyte
Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.